Peptides DB
Research-centric peptide and protocol reference hub
Study 51 of 52NAD+ (Nicotinamide Adenine Dinucleotide) literaturebiorxiv-preprint · Meta-analysis2026

Peripheral Blood NADP(H) Redox Metabolism in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-analysis Where Feasible

This review indicates potential alterations in NADP(H) metabolism in Alzheimer's disease and mild cognitive impairment, but the evidence is inconsistent and lacks direct measurements of key metabolites.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpus
20
Preclinical
23
Observational
2
Open-label
1
Randomised
6
Reviews · this one

Summary and findings

This systematic review and meta-analysis evaluated peripheral-blood NADP(H) redox metabolism and related enzymes in Alzheimer's disease (AD) and mild cognitive impairment (MCI). Thirteen studies were included, focusing on erythrocyte glutathione reductase (GR) and glucose-6-phosphate dehydrogenase (G6PD). The findings indicated inconsistent effects across studies regarding NADP(H)-related enzyme networks.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
pooled effect for erythrocyte GR in AD was g=−1.05 (95% CI −2.73 to 0.63; I 2 =95.0%; five studies)2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Background</h4> The reduced and oxidized forms of nicotinamide adenine dinucleotide phosphate (NADPH/NADP□) connect cellular reducing power with the glutathione and thioredoxin systems. Peripheral alterations in this network may reflect systemic redox dysregulation in Alzheimer’s disease (AD) and mild cognitive impairment (MCI), but the evidence has not been quantitatively synthesized. <h4>Objective</h4> To systematically evaluate peripheral-blood NADP(H) redox metabolism and related enzymes in AD and MCI and to perform meta-analyses when the available data were sufficiently comparable. <h4>Methods</h4> PubMed, Embase, and Web of Science were searched from inception to 6 November 2026. Eligible observational studies compared patients with AD or MCI with cognitively unimpaired controls and reported NADPH, NADP□, the NADPH/NADP□ ratio, or NADPH-related enzymes, including glutathione reductase (GR), glucose-6-phosphate dehydrogenase (G6PD), and thioredoxin reductase (TRXR). Continuous outcomes were converted to Hedges g. Random-effects models used restricted maximum likelihood estimation and modified Hartung–Knapp confidence intervals. <h4>Results</h4> Of 2,686 records identified, 1,781 remained after deduplication and 13 studies were included. No study directly reported peripheral NADPH, NADP□, or the NADPH/NADP□ ratio. The pooled effect for erythrocyte GR in AD was g=−1.05 (95% CI −2.73 to 0.63; I 2 =95.0%; five studies); for erythrocyte GR in MCI, g=−0.15 (95% CI −8.68 to 8.38; I 2 =95.0%; two studies); for whole-blood/plasma GR in AD, g=−0.03 (95% CI −4.37 to 4.30; I 2 =97.1%; three studies); and for erythrocyte G6PD in AD, g=−0.66 (95% CI −17.36 to 16.03; I 2 =96.4%; two studies). Leave-one-out analyses did not materially alter the interpretation of the erythrocyte GR synthesis. <h4>Conclusions</h4> AD and MCI may be accompanied by remodeling of peripheral NADP(H)-related enzyme networks, but the direction and magnitude of effects are inconsistent across studies. Direct measurement of NADPH, NADP□, and their ratio remains the most important evidence gap. Future prospective studies should standardize specimen type, pre-analytical handling, and analytical platforms and should account for disease stage, treatment exposure, and metabolic comorbidity.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the NAD+ (Nicotinamide Adenine Dinucleotide) corpus

CA trapped catalytic product acts as molecular glue for innate immune signalosome assembly.Science (New York, N.Y.) · 2026 · Not reported in abstract.In vitroBCangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial.Lancet (London, England) · 2026HumanDThe bleeding edge of NAD in human ageing.Nature metabolism · 2026—DWhole-blood NAD levels track cardiovascular disease but not chronological age.Nature metabolism · 2026—CBioactive vitamin E-NAD<sup>+</sup> conjugate nanoparticles for osteoarthritis management via simultaneous suppression of inflammation and oxidative stress.Biomaterials · 2026 · Not reported in abstract.AnimalBNAD metabolism mediates a sex-specific protection against early life infectionsbiorxiv-preprint · 2026 · Higher birth NAD levels in females were associated with reduced infection burdens during the first 3 years of life.Human